ForSight Vision5 closes $15 million funding round, completes phase 2 study enrollment

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ForSight Vision5 closed a series C round of funding, which raised $15 million, and completed enrollment in a phase 2 clinical study for the Helios ocular insert, a press release said.

The company, which is developing noninvasive products to replace eye drops and provide sustained therapy for anterior segment eye diseases, completed enrollment of more than 160 subjects in a randomized, active controlled study of the Helios insert in patients with glaucoma and ocular hypertension, according to the release.

The funding was led by H.I.G. BioVentures. Returning investors included Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures.